Ablative Solutions, Inc., receives Innovation Award from Medical Main Street at Inno-vention 2012

KALAMAZOO, Mich., Oct. 9, 2012 /PRNewswire/ -- Ablative Solutions, Inc. (ASI), a privately-held company headquartered in Kalamazoo, MI with offices in Menlo Park, CA announced today that it was a recipient of Innovator of the Year award by Medical Main Street.   Medical Main Street sponsors the Inno-vention 2012 conference, which brings together Michigan-based hospitals, research universities, pharmaceutical companies, medical device companies and researchers, with the goal of promoting innovation in the life sciences field. 

"We are honored to be recognized by Medical Main Street.   We appreciate that the model of collaboration between research universities, hospitals and entrepreneurial companies is an excellent way to drive innovative therapy development.  Ablative Solutions is employing this type of approach in our development of PeriVascular Renal Denervation (PVRD™) technology for a more streamlined treatment of hypertension," stated Dr. Tim Fischell, CEO and CMO of ASI.

ASI was founded in 2011 by two proven medical device entrepreneurs, Tim Fischell, MD and David Fischell, PhD. The Company is developing a unique approach to Renal Denervation, a new therapy that addresses hypertension and other diseases resulting from overactive sympathetic nerve activity.  The sympathetic nerves that run along the renal artery play an essential role in controlling blood pressure but, when overactive, contribute to hypertension and a number of other conditions and diseases. 

Renal Denervation has been demonstrated to reduce blood pressure in patients who are not effectively treated by drug therapy. The deactivation of the nerves, located beside the renal artery, reduces the nerve signaling process, and helps to reduce blood pressure. Unlike approaches to Renal Denervation that deliver destructive energy through the entire renal artery wall, ASI has developed a unique device that circumvents the artery wall and targets treatment directly to the nerves that encircle the renal artery - a solution that ASI calls PeriVascular Renal Denervation or PVRD.

For more information:
Vartan Ghazarossian, PhD
(650) 321-6884

Forward-Looking Statements

This press release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Information in this press release, which is not historical, is forward-looking and involves a number of risks and uncertainties. Investors are cautioned not to put any undue reliance on any forward-looking statement. ASI's actual results may differ materially from ASI's historical results of operations and those discussed in the forward-looking statements for various reasons, including, but not limited to ASI's ability to carry out its business plan, successful development and commercial acceptance of its products, ability to fund development necessary for existing products and for the pursuit of new product opportunities, ability to hire required personnel, the risk of whether products result from development activities, protection of ASI's intellectual property portfolio, the risk associated with obtaining the necessary regulatory approvals, the ability to obtain foreign regulatory approvals for products and to establish marketing arrangements in countries where approval is obtained, and other potential factors.



SOURCE Ablative Solutions, Inc.